Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Intermittent calorie restriction proves as effective as daily calorie cuts for type 2 diabetes

New clinical research suggests both continuous and intermittent calorie restriction improve metabolic health in type 2 diabetes, with adherence emerging as a key factor in real-world success. Study: The effect of continuous or intermittent calorie-restricted d

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

New clinical research suggests both continuous and intermittent calorie restriction improve metabolic health in type 2 diabetes, with adherence emerging as a key factor in real-world success.

Study: The effect of continuous or intermittent calorie-restricted diet on body composition and resting energy expenditure in patients with type 2 diabetes. Image Credit: Oleksandra Mykhailutsa / Shutterstock

In a recent article submitted to the journal Clinical Nutrition ESPEN, a group of researchers evaluated how a three-month continuous calorie-restricted (CCR) diet compared with an intermittent calorie-restricted (ICR) diet affects body composition and resting energy expenditure in adults with type 2 diabetes and overweight or obesity, based on a post-hoc analysis combining participants from two separate randomized trials rather than a direct head-to-head randomized comparison.

Background

More than 500 million people worldwide live with type 2 diabetes, and excess weight remains one of its most significant causes. Losing even a modest amount of weight can improve blood glucose levels, reduce medication requirements, and lower the risk of cardiovascular disease. Traditionally, CCR has been used; however, there is increasing interest in intermittent diets. Both methods can create a caloric deficit, leading to weight loss; however, the amount of fat-free mass, including muscle, determines the magnitude of the decrease in resting energy expenditure after weight loss and may impair long-term maintenance of a healthy weight.

Maintaining muscle during weight loss is vital in older adults with diabetes. Further research is needed to clarify which strategy better protects metabolic health, particularly because between-group comparisons in this study were exploratory and not powered for definitive conclusions, and because the intervention lasted only three months, limiting conclusions about long-term sustainability.

About the study

This post-hoc analysis included adults with type 2 diabetes and a body mass index above 27 kilograms per square meter who participated in two separate ongoing randomized controlled trials in the Netherlands, E-DIET and TIMED, from which intervention groups were pooled for analysis. Participants followed either a CCR diet or an ICR diet for three months.

The CCR group consumed approximately 750 kilocalories per day from meal replacements, with low-carbohydrate vegetables provided in addition to lean protein, low-energy drinks, and skim milk. The ICR group followed an early time-restricted eating pattern, consuming all calories between 8:00 AM and 6:00 PM, with a daily intake of 1300 kilocalories for women and 1500 kilocalories for men, alongside moderate carbohydrate restriction.

Fat mass, fat-free mass, and phase angle, a marker of cellular health and nutritional status rather than hydration alone, were measured using a multi-frequency bioelectrical impedance device to determine body composition. Resting energy expenditure was calculated using indirect calorimetry under controlled laboratory conditions. Glycemic control was evaluated using fasting glucose and glycated hemoglobin. Lipid profile, blood pressure, diabetes medication use (assessed using the Medication Effect Score), dietary intake, physical activity, and treatment satisfaction were also recorded. Statistical analyses examined within-group changes and exploratory comparisons between groups, adjusting for baseline differences such as diabetes duration and glycemic control.

Study results

In total, 67 participants were included in the analysis: 41 in the CCR group and 26 in the ICR group. The average age was approximately 60 years, and more than half were women. Body mass index values were similar between groups at baseline, but diabetes duration was longer in the CCR group, and other metabolic differences were present, limiting direct comparability.

After three months, both diets produced significant weight loss. On average, participants following the CCR diet lost 7.4 kg, whereas those following the ICR diet lost 6.8 kg. Both groups showed significant reductions in body mass index and waist circumference, suggesting reduced central adiposity rather than a direct reduction in abdominal fat.

Fat mass decreased significantly in both groups. The percentage of fat-free mass increased in both interventions, although absolute fat-free mass declined modestly in the ICR group, indicating that percentage increases do not necessarily reflect true muscle gain. Absolute fat-free mass was preserved in the CCR group and decreased modestly in the ICR group, representing approximately 20 percent of total weight loss, consistent with expected physiological adaptation. Muscle strength or sarcopenia was not directly assessed.

Resting energy expenditure decreased significantly only in the CCR group. This decrease may reflect adaptive thermogenesis rather than solely fat-free mass loss, as the body conserves energy during substantial caloric restriction. In practical terms, lower resting energy expenditure may make long-term weight maintenance more challenging.

Glycated hemoglobin improved significantly in the CCR group, while fasting glucose did not change significantly in either group. Both groups reduced diabetes medication use, as reflected by reductions in Medication Effect Score rather than by confirmed medication discontinuation. Total cholesterol and low-density lipoprotein cholesterol improved significantly in the CCR group, while high-density lipoprotein cholesterol increased in the ICR group. Triglycerides decreased in both groups. Blood pressure improved significantly only in the CCR group.

Dietary intake data showed substantial calorie reduction in both groups, with a greater decrease in the CCR group. The percentage of protein intake relative to total energy intake increased in both groups, although no direct correlation was observed between protein intake and fat-free mass preservation.

Dropout rates differed, 19% in the CCR group and 0% in the ICR group. This suggests time-restricted eating may be easier to follow in the short term, although interpretation should remain cautious given baseline differences, different physical activity assessment methods, and the short three-month duration.

Formal exploratory regression analyses showed no statistically significant differences between diets for body composition, resting energy expenditure, glycemic outcomes, or cardiometabolic measures, with dropout rate being the primary observed difference.

Conclusions

Both CCR and ICR diets significantly improved body composition in adults with type 2 diabetes and overweight or obesity over three months, without evidence of excessive loss of fat-free mass. While resting energy expenditure declined only in the CCR group, metabolic improvements were observed with both approaches. The lower dropout rate in the ICR group suggests greater short-term feasibility, though longer-term adherence remains uncertain. Longer-term randomized controlled trials are needed to determine the durability, metabolic adaptations, and clinical outcomes associated with these dietary strategies.

  • Dietvorst C, Geurts K, Lodari O, Boon M, van Rossum E, Visser W, & Berk K. (2026). The effect of continuous or intermittent calorie-restricted diet on body composition and resting energy expenditure in patients with type 2 diabetes. Clinical Nutrition ESPEN. DOI: 10.1016/j.clnesp.2026.102940, https://www.clinicalnutritionespen.com/article/S2405-4577(26)00035-5/pdf

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What is carb cycling?

Carb cycling is an attempt to fine-tune your carbohydrate consumption to alter many aspects of your metabolism. Your plan will include the same protein intake each day but vary carbohydrates according to your activity. Your carb cycling plan may have three low or zero carb days, two moderate carb days, and two high carb days. Meeting your calorie requirements will require including more fats on low-carb days. Carb cycling needs much more planning than a usual calorie-controlled diet. One way is to match your carb cycling to your physical activity. If you go to the gym thrice a week, you could have carbs on those days. The carbs provide energy for your workout, prevent fatigue, and avoid the muscle loss sometimes seen with dieting. The days when you eat little to no carbs force your body to generate energy from other sources, like proteins and fats. But the days when you eat more carbohydrates might reverse this change. You must only eat a high-carb diet on the days you have a heavy workout, which uses up the calories.

Source: www.medicinenet.com ↗
02Can you please give an overview of BenevolentBio?

What we're trying to do here at Benevolent is develop systems and processes that allow us to tap into the huge amount of public information and some propriety databases that we have paid to access and through that, generate hypotheses which our scientists can then triage. We've got over ten times the amount of information in our database at present (and it’s growing) than we believe that companies such as Watson have. Bringing that and filtering the signals from the ‘noise’ to our experienced drug discovery chemists and biologists, means, firstly, we can reduce the amount of time we take to triage new hypotheses, and secondly, we can develop more predictive chemical tools to allow us to make better molecules and also to reposition existing molecules for new indication.

Source: www.news-medical.net ↗
03Your early research focused on predicting molecular properties such as solubility using machine learning. What did that teach you about data-driven property prediction?

Data-driven models, such as Quantitative Structure Activity Relationships (QSAR), are incredibly attractive because they offer rapid methods for predicting molecular properties, including those that are difficult to access through fundamental chemical and physical theory. For new molecules, in related regions of chemical space to the training data, they can often be very accurate. The challenge is that they typically do not generalize across large diverse chemical and biological spaces. Therefore real care is needed when applying them to novel chemistry or biology. Some attempts to build more widely applicable QSAR models have been made in recent years, but most models in use today are still built for specific chemistries and properties owing to the scale and complexity of chemical space. When I started this work, especially for solubility predictions, the datasets were modest by today’s standards, often hundreds to a few thousand molecules. One of the first things that teaches you is to explore the data carefully, assess its quality and quantity, and only then move forward with modeling. The aim is to capture genuine relationships between numerical molecular descriptions and important target endpoints, but those relationships may be only locally generalizable. I also think the phrase “simple descriptors” is interesting. Some are simple, such as atom counts or bond counts, but others rely on detailed parameterization, group contributions, and graph-theoretical techniques. We still see these descriptors used today, sometimes alongside embeddings from graph neural networks or language models. The main lesson for me is that there is no single workflow. Each dataset, model, and end-use case needs careful thought.

Source: www.news-medical.net ↗
04How does vitamin D strengthen the immune system?

More specifically, the study showed that the female patient produced very few cathelicidins, which is a natural toxin found in the immune cells of the lungs needed to fight tuberculosis. In most people infected by tuberculosis, tuberculosis bacteria attack the immune cells of the lungs. The immune cells fight the bacteria by eating them. But the tuberculosis bacterium has developed various evasive mechanisms that reduce the immune cells’ ability to digest and thus to kill the Mtb. “You could say that the tuberculosis bacterium has developed a way to lull the immune cells to sleep. This enables the disease the hide inside the immune cells, making it invisible to other parts of the immune system,” Martin Kongsbak-Wismann explains. This is where vitamin D enters the picture. Because vitamin D is able to counteract the soporific effect of the tuberculosis bacteria by making the immune cells produce more of the cathelicidin toxin. “Cathelicidin is like a microscopic needle that is able to pierce the tuberculosis bacteria. And when it does, it weakens the bacteria’s soporific effect on the immune cells. This restores the immune cells’ ability to kill tuberculosis bacteria,” says Martin Kongsbak-Wismann and adds: “We were amazed by the effect of vitamin D. In immune cells from healthy control subjects, vitamin D improved the cells’ ability to fight Mtb, whereas in the female patient’s immune cells we saw no response to vitamin D. This shows that vitamin D is key to the immune system’s ability to fight Mtb and prevent tuberculosis.” Al-Jaberi, F.A.H., et al. (2022) Reduced vitamin D-induced cathelicidin production and killing of Mycobacterium tuberculosis in macrophages from a patient with a non-functional vitamin D receptor: A case report. Frontiers in Immunology. doi.org/10.3389/fimmu.2022.1038960.

Source: www.news-medical.net ↗
05How will this discovery change cancer science?

This is a win for the field. Until now, we have been focused on immune therapies that might make tumors more vulnerable to the body's immune system, and on finding new chemotherapy combinations that kill cancer cells. This new treatment has given us a new focus, and I think it will spur a lot of scientific discovery over the next few years. There have only been a handful of KRAS researchers and their relevance to therapy was always questioned. That is about to change. The most important next step for the field is to better understand the biology of cancer. We know that many pancreatic tumors will eventually become resistant to daraxonrasib, and we need to understand how this happens. We also need to identify additional genetic pathways and treatments that can target them. That's how we will turn pancreas cancer from a deadly, deadly cancer into something we can manage-and one day, even cure.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides